Amylyx Pharmaceuticals (AMLX) Liabilities and Shareholders Equity (2021 - 2026)

Amylyx Pharmaceuticals' Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $293.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity rose 33.65% year-over-year to $293.6 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 18.81% YoY), while the FY2025 annual figure was $332.6 million, up 71.79% from the prior year.
• Liabilities and Shareholders Equity was $293.6 million for Q1 2026 at Amylyx Pharmaceuticals, down from $332.6 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $517.5 million in Q4 2023 to a low of $181.4 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $324.4 million across 5 years, with a median of $332.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 270.64% in 2022, then plunged 62.58% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $391.5 million in 2022, then jumped by 32.19% to $517.5 million in 2023, then slumped by 62.58% to $193.6 million in 2024, then soared by 71.79% to $332.6 million in 2025, then fell by 11.74% to $293.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $293.6 million (Q1 2026), $332.6 million (Q4 2025), and $362.7 million (Q3 2025), per Business Quant data.